BMRN Biomarin Pharmaceutical Inc
Company Analysis
Latest News
Biomarin Pharmaceutical Inc Q3 2026 Earnings Preview: What Analysts Expect on October 26, 2026
Consensus expectations point to Q3 2026 revenue of $722.40 million and EPS of $0.52, as the stock trades at $94.15 relative to a $118.50 analyst price...
BioMarin Pharmaceutical expects $1.50 third quarter 2026 EPS headwind from Alesta acquisition
BioMarin Pharmaceutical announced preliminary financial impacts regarding its acquisition of Alesta Therapeutics, which closed on August 31, 2026. The company...
BioMarin Finalizes Patent License Agreement with Ascendis for TransCon CNP Royalties
BioMarin Pharmaceutical Inc. has entered into a definitive Settlement and License Agreement with Ascendis Pharma A/S, resolving all pending patent litigation...
BioMarin Discontinues VOXZOGO Development Program for Noonan Syndrome
BioMarin Pharmaceutical Inc. announced it is discontinuing the development of its drug, VOXZOGO, for the treatment of children with Noonan syndrome. The...
BioMarin Completes Acquisition of Alesta Therapeutics B.V.
BioMarin Pharmaceutical Inc. has announced the completion of its previously disclosed acquisition of Alesta Therapeutics B.V. The transaction, a share...
BioMarin Enters Global Patent Settlement with Ascendis Pharma for Royalty Payments
BioMarin Pharmaceutical Inc. has entered into a binding global settlement and license agreement with Ascendis Pharma A/S, resolving all pending patent-related...
Steve Cohen's Point72 Exits BioMarin (BMRN) Stake
Steve Cohen's Point72 Asset Management fully liquidated its position in BioMarin Pharmaceutical Inc. (BMRN) during the second quarter of 2026. The firm sold...
BioMarin to Acquire Alesta Therapeutics for up to $490 Million
BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire Alesta Therapeutics B.V., a private Dutch company that develops oral small...
BioMarin second quarter 2026 revenue beats expectations on Amicus integration and raised 2026 guidance
BioMarin Pharmaceutical reported a significant top-line expansion in the second quarter of 2026, driven by the successful closing of the Amicus Therapeutics...
Biomarin Pharmaceutical Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Analysts expect BioMarin Pharmaceutical to report Q2 2026 revenue of $931.3 million and non-GAAP EPS of $0.79, while the stock currently trades at $60.02, well...